User login
A strategy developed by Canadian researchers for encouraging older patients with insomnia to wean themselves from sleeping pills and improve their sleep through behavioral techniques is effective, data suggest. If proven helpful for the millions of older Canadians who currently rely on nightly benzodiazepines (BZDs) and non-BZDs (colloquially known as Z drugs) for their sleep, it might yield an additional benefit: Reducing resource utilization.
“We know that cognitive behavioral therapy for insomnia (CBTI) works. It’s recommended as first-line therapy because it works,” study author David Gardner, PharmD, professor of psychiatry at Dalhousie University in Halifax, Nova Scotia, Canada, told this news organization.
“We’re sharing information about sleeping pills, information that has been embedded with behavior-change techniques that lead people to second-guess or rethink their long-term use of sedative hypnotics and then bring that information to their provider or pharmacist to discuss it,” he said.
The results were published in JAMA Psychiatry.
Better Sleep, Fewer Pills
Dr. Gardner and his team created a direct-to-patient, patient-directed, multicomponent knowledge mobilization intervention called Sleepwell. It incorporates best practice– and guideline-based evidence and multiple behavioral change techniques with content and graphics. Dr. Gardner emphasized that it represents a directional shift in care that alleviates providers’ burden without removing it entirely.
To test the intervention’s effectiveness, Dr. Gardner and his team chose New Brunswick as a location for a 6-month, three-arm, open-label, randomized controlled trial; the province has one of the highest rates of sedative use and an older adult population that is vulnerable to the serious side effects of these drugs (eg, cognitive impairment, falls, and frailty). The study was called Your Answers When Needing Sleep in New Brunswick (YAWNS NB).
Eligible participants were aged ≥ 65 years, lived in the community, and had taken benzodiazepine receptor agonists (BZRAs) for ≥ 3 nights per week for 3 or more months. Participants were randomly assigned to a control group or one of the two intervention groups. The YAWNS-1 intervention group (n = 195) received a mailed package containing a cover letter, a booklet outlining how to stop sleeping pills, a booklet on how to “get your sleep back,” and a companion website. The YAWNS-2 group (n = 193) received updated versions of the booklets used in a prior trial. The control group (n = 192) was assigned treatment as usual (TAU).
A greater proportion of YAWNS-1 participants discontinued BZRAs at 6 months (26.2%) and had dose reductions (20.4%), compared with YAWNS-2 participants (20.3% and 14.4%, respectively) and TAU participants (7.5% and 12.8%, respectively). The corresponding numbers needed to mail to achieve an additional discontinuation was 5.3 YAWNS-1 packages and 7.8 YAWNS-2 packages.
At 6 months, BZRA cessation was sustained a mean 13.6 weeks for YAWNS-1, 14.3 weeks for YAWNS-2, and 16.9 weeks for TAU.
Sleep measures also improved with YAWNS-1, compared with YAWNs-2 and TAU. Sleep onset latency was reduced by 26.1 minutes among YAWNS-1 participants, compared with YAWNS-2 (P < .001), and by 27.7 minutes, compared with TAU (P < .001). Wake after sleep onset increased by 4.1 minutes in YAWNS-1, 11.1 minutes in YAWNS-2, and 7.5 minutes in TAU.
Although all participants underwent rigorous assessment before inclusion, less than half of participants receiving either intervention (36% in YAWNS-1 and 43% in YAWNS-2) contacted their provider or pharmacist to discuss BZD dose reductions. This finding may have resulted partly from limited access because of the COVID-19 pandemic, according to the authors.
A Stepped-Care Model
The intervention is intended to help patients “change their approach from sleeping pills to a short-term CBTI course for long-term sleep benefits, and then speak to their provider,” said Dr. Gardner.
He pointed to a post-study follow-up of the study participants’ health providers, most of whom had moderate to extensive experience deprescribing BZRAs, which showed that 87.5%-100% fully or nearly fully agreed with or supported using the Sleepwell strategy and its content with older patients who rely on sedatives.
“Providers said that deprescribing is difficult, time-consuming, and often not a productive use of their time,” said Dr. Gardner. “I see insomnia as a health issue well set up for a stepped-care model. Self-help approaches are at the very bottom of that model and can help shift the initial burden to patients and out of the healthcare system.”
Poor uptake has prevented CBTI from demonstrating its potential, which is a challenge that Charles M. Morin, PhD, professor of psychology at Laval University in Quebec City, Quebec, Canada, attributes to two factors. “Clearly, there aren’t enough providers with this kind of expertise, and it’s not always covered by public health insurance, so people have to pay out of pocket to treat their insomnia,” he said.
“Overall, I think that this was a very nice study, well conducted, with an impressive sample size,” said Dr. Morin, who was not involved in the study. “The results are quite encouraging, telling us that even when older adults have used sleep medications for an average of 10 years, it’s still possible to reduce the medication. But this doesn’t happen alone. People need to be guided in doing that, not only to decrease medication use, but they also need an alternative,” he said.
Dr. Morin questioned how many patients agree to start with a low intensity. “Ideally, it should be a shared decision paradigm, where the physician or whoever sees the patient first presents the available options and explains the pluses and minuses of each. Some patients might choose medication because it’s a quick fix,” he said. “But some might want to do CBTI, even if it takes more work. The results are sustainable over time,” he added.
The study was jointly funded by the Public Health Agency of Canada and the government of New Brunswick as a Healthy Seniors Pilot Project. Dr. Gardner and Dr. Morin reported no relevant financial relationships.
A version of this article first appeared on Medscape.com.
A strategy developed by Canadian researchers for encouraging older patients with insomnia to wean themselves from sleeping pills and improve their sleep through behavioral techniques is effective, data suggest. If proven helpful for the millions of older Canadians who currently rely on nightly benzodiazepines (BZDs) and non-BZDs (colloquially known as Z drugs) for their sleep, it might yield an additional benefit: Reducing resource utilization.
“We know that cognitive behavioral therapy for insomnia (CBTI) works. It’s recommended as first-line therapy because it works,” study author David Gardner, PharmD, professor of psychiatry at Dalhousie University in Halifax, Nova Scotia, Canada, told this news organization.
“We’re sharing information about sleeping pills, information that has been embedded with behavior-change techniques that lead people to second-guess or rethink their long-term use of sedative hypnotics and then bring that information to their provider or pharmacist to discuss it,” he said.
The results were published in JAMA Psychiatry.
Better Sleep, Fewer Pills
Dr. Gardner and his team created a direct-to-patient, patient-directed, multicomponent knowledge mobilization intervention called Sleepwell. It incorporates best practice– and guideline-based evidence and multiple behavioral change techniques with content and graphics. Dr. Gardner emphasized that it represents a directional shift in care that alleviates providers’ burden without removing it entirely.
To test the intervention’s effectiveness, Dr. Gardner and his team chose New Brunswick as a location for a 6-month, three-arm, open-label, randomized controlled trial; the province has one of the highest rates of sedative use and an older adult population that is vulnerable to the serious side effects of these drugs (eg, cognitive impairment, falls, and frailty). The study was called Your Answers When Needing Sleep in New Brunswick (YAWNS NB).
Eligible participants were aged ≥ 65 years, lived in the community, and had taken benzodiazepine receptor agonists (BZRAs) for ≥ 3 nights per week for 3 or more months. Participants were randomly assigned to a control group or one of the two intervention groups. The YAWNS-1 intervention group (n = 195) received a mailed package containing a cover letter, a booklet outlining how to stop sleeping pills, a booklet on how to “get your sleep back,” and a companion website. The YAWNS-2 group (n = 193) received updated versions of the booklets used in a prior trial. The control group (n = 192) was assigned treatment as usual (TAU).
A greater proportion of YAWNS-1 participants discontinued BZRAs at 6 months (26.2%) and had dose reductions (20.4%), compared with YAWNS-2 participants (20.3% and 14.4%, respectively) and TAU participants (7.5% and 12.8%, respectively). The corresponding numbers needed to mail to achieve an additional discontinuation was 5.3 YAWNS-1 packages and 7.8 YAWNS-2 packages.
At 6 months, BZRA cessation was sustained a mean 13.6 weeks for YAWNS-1, 14.3 weeks for YAWNS-2, and 16.9 weeks for TAU.
Sleep measures also improved with YAWNS-1, compared with YAWNs-2 and TAU. Sleep onset latency was reduced by 26.1 minutes among YAWNS-1 participants, compared with YAWNS-2 (P < .001), and by 27.7 minutes, compared with TAU (P < .001). Wake after sleep onset increased by 4.1 minutes in YAWNS-1, 11.1 minutes in YAWNS-2, and 7.5 minutes in TAU.
Although all participants underwent rigorous assessment before inclusion, less than half of participants receiving either intervention (36% in YAWNS-1 and 43% in YAWNS-2) contacted their provider or pharmacist to discuss BZD dose reductions. This finding may have resulted partly from limited access because of the COVID-19 pandemic, according to the authors.
A Stepped-Care Model
The intervention is intended to help patients “change their approach from sleeping pills to a short-term CBTI course for long-term sleep benefits, and then speak to their provider,” said Dr. Gardner.
He pointed to a post-study follow-up of the study participants’ health providers, most of whom had moderate to extensive experience deprescribing BZRAs, which showed that 87.5%-100% fully or nearly fully agreed with or supported using the Sleepwell strategy and its content with older patients who rely on sedatives.
“Providers said that deprescribing is difficult, time-consuming, and often not a productive use of their time,” said Dr. Gardner. “I see insomnia as a health issue well set up for a stepped-care model. Self-help approaches are at the very bottom of that model and can help shift the initial burden to patients and out of the healthcare system.”
Poor uptake has prevented CBTI from demonstrating its potential, which is a challenge that Charles M. Morin, PhD, professor of psychology at Laval University in Quebec City, Quebec, Canada, attributes to two factors. “Clearly, there aren’t enough providers with this kind of expertise, and it’s not always covered by public health insurance, so people have to pay out of pocket to treat their insomnia,” he said.
“Overall, I think that this was a very nice study, well conducted, with an impressive sample size,” said Dr. Morin, who was not involved in the study. “The results are quite encouraging, telling us that even when older adults have used sleep medications for an average of 10 years, it’s still possible to reduce the medication. But this doesn’t happen alone. People need to be guided in doing that, not only to decrease medication use, but they also need an alternative,” he said.
Dr. Morin questioned how many patients agree to start with a low intensity. “Ideally, it should be a shared decision paradigm, where the physician or whoever sees the patient first presents the available options and explains the pluses and minuses of each. Some patients might choose medication because it’s a quick fix,” he said. “But some might want to do CBTI, even if it takes more work. The results are sustainable over time,” he added.
The study was jointly funded by the Public Health Agency of Canada and the government of New Brunswick as a Healthy Seniors Pilot Project. Dr. Gardner and Dr. Morin reported no relevant financial relationships.
A version of this article first appeared on Medscape.com.
A strategy developed by Canadian researchers for encouraging older patients with insomnia to wean themselves from sleeping pills and improve their sleep through behavioral techniques is effective, data suggest. If proven helpful for the millions of older Canadians who currently rely on nightly benzodiazepines (BZDs) and non-BZDs (colloquially known as Z drugs) for their sleep, it might yield an additional benefit: Reducing resource utilization.
“We know that cognitive behavioral therapy for insomnia (CBTI) works. It’s recommended as first-line therapy because it works,” study author David Gardner, PharmD, professor of psychiatry at Dalhousie University in Halifax, Nova Scotia, Canada, told this news organization.
“We’re sharing information about sleeping pills, information that has been embedded with behavior-change techniques that lead people to second-guess or rethink their long-term use of sedative hypnotics and then bring that information to their provider or pharmacist to discuss it,” he said.
The results were published in JAMA Psychiatry.
Better Sleep, Fewer Pills
Dr. Gardner and his team created a direct-to-patient, patient-directed, multicomponent knowledge mobilization intervention called Sleepwell. It incorporates best practice– and guideline-based evidence and multiple behavioral change techniques with content and graphics. Dr. Gardner emphasized that it represents a directional shift in care that alleviates providers’ burden without removing it entirely.
To test the intervention’s effectiveness, Dr. Gardner and his team chose New Brunswick as a location for a 6-month, three-arm, open-label, randomized controlled trial; the province has one of the highest rates of sedative use and an older adult population that is vulnerable to the serious side effects of these drugs (eg, cognitive impairment, falls, and frailty). The study was called Your Answers When Needing Sleep in New Brunswick (YAWNS NB).
Eligible participants were aged ≥ 65 years, lived in the community, and had taken benzodiazepine receptor agonists (BZRAs) for ≥ 3 nights per week for 3 or more months. Participants were randomly assigned to a control group or one of the two intervention groups. The YAWNS-1 intervention group (n = 195) received a mailed package containing a cover letter, a booklet outlining how to stop sleeping pills, a booklet on how to “get your sleep back,” and a companion website. The YAWNS-2 group (n = 193) received updated versions of the booklets used in a prior trial. The control group (n = 192) was assigned treatment as usual (TAU).
A greater proportion of YAWNS-1 participants discontinued BZRAs at 6 months (26.2%) and had dose reductions (20.4%), compared with YAWNS-2 participants (20.3% and 14.4%, respectively) and TAU participants (7.5% and 12.8%, respectively). The corresponding numbers needed to mail to achieve an additional discontinuation was 5.3 YAWNS-1 packages and 7.8 YAWNS-2 packages.
At 6 months, BZRA cessation was sustained a mean 13.6 weeks for YAWNS-1, 14.3 weeks for YAWNS-2, and 16.9 weeks for TAU.
Sleep measures also improved with YAWNS-1, compared with YAWNs-2 and TAU. Sleep onset latency was reduced by 26.1 minutes among YAWNS-1 participants, compared with YAWNS-2 (P < .001), and by 27.7 minutes, compared with TAU (P < .001). Wake after sleep onset increased by 4.1 minutes in YAWNS-1, 11.1 minutes in YAWNS-2, and 7.5 minutes in TAU.
Although all participants underwent rigorous assessment before inclusion, less than half of participants receiving either intervention (36% in YAWNS-1 and 43% in YAWNS-2) contacted their provider or pharmacist to discuss BZD dose reductions. This finding may have resulted partly from limited access because of the COVID-19 pandemic, according to the authors.
A Stepped-Care Model
The intervention is intended to help patients “change their approach from sleeping pills to a short-term CBTI course for long-term sleep benefits, and then speak to their provider,” said Dr. Gardner.
He pointed to a post-study follow-up of the study participants’ health providers, most of whom had moderate to extensive experience deprescribing BZRAs, which showed that 87.5%-100% fully or nearly fully agreed with or supported using the Sleepwell strategy and its content with older patients who rely on sedatives.
“Providers said that deprescribing is difficult, time-consuming, and often not a productive use of their time,” said Dr. Gardner. “I see insomnia as a health issue well set up for a stepped-care model. Self-help approaches are at the very bottom of that model and can help shift the initial burden to patients and out of the healthcare system.”
Poor uptake has prevented CBTI from demonstrating its potential, which is a challenge that Charles M. Morin, PhD, professor of psychology at Laval University in Quebec City, Quebec, Canada, attributes to two factors. “Clearly, there aren’t enough providers with this kind of expertise, and it’s not always covered by public health insurance, so people have to pay out of pocket to treat their insomnia,” he said.
“Overall, I think that this was a very nice study, well conducted, with an impressive sample size,” said Dr. Morin, who was not involved in the study. “The results are quite encouraging, telling us that even when older adults have used sleep medications for an average of 10 years, it’s still possible to reduce the medication. But this doesn’t happen alone. People need to be guided in doing that, not only to decrease medication use, but they also need an alternative,” he said.
Dr. Morin questioned how many patients agree to start with a low intensity. “Ideally, it should be a shared decision paradigm, where the physician or whoever sees the patient first presents the available options and explains the pluses and minuses of each. Some patients might choose medication because it’s a quick fix,” he said. “But some might want to do CBTI, even if it takes more work. The results are sustainable over time,” he added.
The study was jointly funded by the Public Health Agency of Canada and the government of New Brunswick as a Healthy Seniors Pilot Project. Dr. Gardner and Dr. Morin reported no relevant financial relationships.
A version of this article first appeared on Medscape.com.